[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591103":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":59,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"HJN Sverige AB\u002FNeko Health","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"patient_cohort",null,"Adult patients mainly from a primary care cohort. All patients visiting the clinical sites, seeking care, or as separately invited, are offered to participate in this investigation. This includes sub-groups of patients with conditions such as diabetes mellitus, peripheral arterial disease and skin cancer. All participants undergo at least one examination with the investigational device (TCI P3).",[13],{"name":14,"affiliation":15,"role":16},"Samuel Rodgers, MD","HJN Sverige AB\u002FNeko Health AB","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Mattias Windå, MSc","CONTACT","+46703169040","mattias@nekohealth.com",[24,43,51],{"facility":25,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Atrium Health Care Centre","RECRUITING","Stockholm","Sweden","SE",{"type":31,"coordinates":32},"Point",[33,34],18.06871,59.32938,{"lat":34,"lon":33},[37,41],{"name":38,"role":20,"phone":39,"phoneExt":10,"email":40},"Andreea Valdman, MD","+4673 939 27 11","andreea@nekohealth.com",{"name":42,"role":16,"phone":10,"phoneExt":10,"email":10},"Samuel Rodgers, MBBS",{"facility":44,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":45,"geoPoint":47,"contacts":48},"Neko Health Centre, Regeringsgatan",{"type":31,"coordinates":46},[33,34],{"lat":34,"lon":33},[49,50],{"name":38,"role":20,"phone":39,"phoneExt":10,"email":40},{"name":42,"role":16,"phone":10,"phoneExt":10,"email":10},{"facility":52,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"Neko Health Centre, Sibyllegatan",{"type":31,"coordinates":54},[33,34],{"lat":34,"lon":33},[57,58],{"name":38,"role":20,"phone":39,"phoneExt":10,"email":40},{"name":42,"role":16,"phone":10,"phoneExt":10,"email":10},{"type":60,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100591103","non-invasive-imaging-for-in-vivo-quantification-of-skin-composition-and-structure-100591103",false,"NCT06976073","Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure","Spectrum1","Inclusion Criteria:\n\n* Adult patients part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation.\n* Patients with signed informed consent\n\nExclusion Criteria:\n\n* Cognitive impairment\n* Patients unable to understand the oral and written study information in Swedish or English\n* Other severe disorder or terminal disease\n* Patients unable to provide an informed consent\n* Patient´s with damaged, scarred or non-intact skin within the skin area of interest.",true,"ALL","18 Years",{"count":72,"type":73},8000,"ESTIMATED","OBSERVATIONAL","The goal of this clinical investigation is to explore a non-invasive technology for measuring the microcirculatory structure, composition and function in patients from a primary care population.\n\nThe main aims are:\n\n1. To evaluate the robustness of the technology for assessment of the molecular composition and structure of the skin tissue and microcirculatory function, on a prospective primary care population.\n2. To evaluate the device and method on its capability to detect deficiencies in circulation, compared with existing reference systems with similar characteristics for patients with known cardiovascular disease risk and\u002For diabetes.",[77,78,79,80,81],"Diabetes Mellitus, Type 2","Diabetic Foot","Peripheral Arterial Disease","Skin Cancer","Cardiovascular Disease Risk","2025-05-08",{"date":84,"type":85},"2025-05-16","ACTUAL",{"date":87,"type":85},"2023-02-01",{"date":89,"type":73},"2026-01-01",{"name":5,"class":6},3]